![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
The collaboration will focus on developing a customized version of the SG EZ-be Pod®, a wearable drug delivery device, for Bexson’s proprietary ketamine formulation, BB106.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Neurology Product Name: BB106
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Bexson Biomedical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 21, 2020